EUVIMEDEUVIMED entdecken
Open Access

Multiple cancers escape from multiple MAPK pathway inhibitors and use DNA replication stress signaling to tolerate aberrant cell cycles

Timothy E Hoffman iD, Varuna Nangia iD, C Ryland Ill iD, Victor J Passanisi iD, Claire Armstrong iD, Chen Yang, Sabrina L Spencer iD

Science Signaling · 2023

DOI: 10.1126/scisignal.ade8744 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Signaling, 2023. Verfasst von Timothy E Hoffman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Biofrontiers Institute, University of Colorado Boulder, Boulder, CO 80303, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Many cancers harbor pro-proliferative mutations of the mitogen-activated protein kinase (MAPK) pathway. In BRAF-driven melanoma cells treated with BRAF inhibitors, subpopulations of cells escape drug-induced quiescence through a nongenetic manner of adaptation and resume slow proliferation. Here, we found that this phenomenon is common to many cancer types driven by EGFR, KRAS, or BRAF mutations in response to multiple, clinically approved MAPK pathway inhibitors. In 2D cultures and 3D spheroid models of various cancer cell lines, a subset of cells escaped drug-induced quiescence within 4 days to resume proliferation. These “escapee” cells exhibited DNA replication deficits, accumulated DNA lesions, and mounted a stress response that depended on the ataxia telangiectasia and RAD3-related (ATR) kinase. We further identified that components of the Fanconi anemia (FA) DNA repair pathway are recruited to sites of mitotic DNA synthesis (MiDAS) in escapee cells, enabling successful completion of cell division. Analysis of patient tumor samples and clinical data correlated disease progression with an increase in DNA replication stress response factors. Our findings suggest that many MAPK pathway–mutant cancers rapidly escape drug action and that suppressing early stress tolerance pathways may achieve more durable clinical responses to MAPK pathway inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafNeoplasmsHumansCell Line, TumorMutationProtein Kinase InhibitorsDNA ReplicationCell Cycle ProteinsCell CycleMAP Kinase Signaling System

Substanzen

Proto-Oncogene Proteins B-rafProtein Kinase InhibitorsCell Cycle Proteins

Autor:innen und Institutionen

  • Department of Biochemistry and Biofrontiers Institute, University of Colorado Boulder, Boulder, CO 80303, USA.
  • Medical Scientist Training Program, University of Colorado-Anschutz Medical School, Aurora, CO 80045, USA.
  • Molecular Cellular and Developmental Biology, University of Colorado Boulder, Boulder, CO 80303, USA.

ORCID-Profile: Timothy E Hoffman, Varuna Nangia, C Ryland Ill, Victor J Passanisi, Claire Armstrong, Sabrina L Spencer

Förderung

  • NIH HHS
  • NCI NIH HHS

Zitieren

APA

Hoffman, T. E., Nangia, V., Ill, C. R., Passanisi, V. J., Armstrong, C., Yang, C., & Spencer, S. L. (2023). Multiple cancers escape from multiple MAPK pathway inhibitors and use DNA replication stress signaling to tolerate aberrant cell cycles. Science Signaling. https://doi.org/10.1126/scisignal.ade8744

Vancouver

Hoffman TE, Nangia V, Ill CR, Passanisi VJ, Armstrong C, Yang C, et al. Multiple cancers escape from multiple MAPK pathway inhibitors and use DNA replication stress signaling to tolerate aberrant cell cycles. Science Signaling. 2023. doi:10.1126/scisignal.ade8744

BibTeX
@article{Hoffman2023,
  author = {Hoffman, Timothy E and Nangia, Varuna and Ill, C Ryland and Passanisi, Victor J and Armstrong, Claire and Yang, Chen and Spencer, Sabrina L},
  title = {Multiple cancers escape from multiple MAPK pathway inhibitors and use DNA replication stress signaling to tolerate aberrant cell cycles},
  journal = {Science Signaling},
  year = {2023},
  doi = {10.1126/scisignal.ade8744}
}
Kostenlos starten →